CMDBioscience Was Named A "2011 Company To Watch" By The Cantor Colburn/ Ccat Innovation And Entrepreneurship Summit

CMDBioscience announced today that they were named a "2011 company to watch" for the Cantor Colburn/ CCAT Innovation and Entrepreneurship Summit. The selection was from more than 100 start up and emerging companies that applied to present at the event which will take place on October 27th in New Haven, CT. End Quote

New Haven-Meriden, CT (1888PressRelease) October 12, 2011 - "We are very pleased to have received this award and look forward to participating in this year's event. This award, among other accomplishments, further validates our technology, business model and market focus. This provides us with another opportunity to showcase our fully validated computational peptide discovery platform CMDInventusSM and further illustrates the value it can provide to partner companies and investors," said Joseph Audie, PhD, CEO for CMDBioscience.

"We are thrilled that CMD has been named to the list of "2011 CT Tech Companies to Watch,'" said Charlie Moret, managing director, business development for Connecticut Innovations. "We believe CMD is in a position to help partner companies significantly accelerate peptide discovery. CMD was one of the first startups supported through our Pre-Seed Fund and is a tenant in our CTech business incubator, where it is utilizing a full complement of resources to help it grow."

About CMDBioscience: CMDBioscienceSM is a computational biotechnology company that specializes in the computer-aided analysis, modeling and design of therapeutic protein-peptide interactions. Using computer-aided peptide design, CMD scientists can drive internal discovery projects and help partner organizations efficiently identify novel peptide hits, understand the structural basis of protein-peptide interactions, and rationally optimize peptide leads.

About CMDInventus: CMDInventusSM offers pharmaceutical, biotech and life science companies a ground breaking tool to assist with their peptide discovery projects. CMDInventusSM has been fully validated by multiple research projects, including a project aimed at identifying novel dengue virus anti-infective agents. CMDBioscience scientists used CMDInventusSM to model a key dengue viral protein structural motif and rationally design small peptides to bind the motif. The project, completed in seven weeks, involved the explicit consideration of 480,000 peptide sequences and ultimately converged on the 27 most promising peptides. Subsequent synthesis and experimental testing revealed excellent anti-infective activity for 5 of the designed peptides.

CMD Bioscience contact:
www.cmdbioscience.com
Mark Jarosinski, PhD
Director, Business Development
mark.jarosinski ( @ ) cmdbioscience dot com
Phone 317-313-9713

###

Visit Cmdbioscience Website

space